Results 1 to 10 of about 146,874 (392)

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

New England Journal of Medicine, 2022
BACKGROUND Trastuzumab emtansine is the current standard treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer whose disease progresses after treatment with a combination of anti-HER2 antibodies and
J. Cortés, Sung-Bae Kim, Wei-Pang Chung, S. Im, Yeon-Hee Park, R. Hegg, Min Hwan Kim, L. Tseng, V. Petry, Chi-Feng Chung, H. Iwata, E. Hamilton, G. Curigliano, Bing-he Xu, Chiun-Sheng Huang, J. Kim, J. Chiu, J. Pedrini, Caleb Lee, Yali Liu, J. Cathcart, E. Bako, S. Verma, S. Hurvitz   +23 more
semanticscholar   +6 more sources

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial

Nature Medicine, 2022
Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We conducted the prospective, open-label, single-arm, phase 2 TUXEDO-1 trial.
Anna Sophie Berghoff, Maximilian Marhold, Rainer Puhr   +2 more
exaly   +2 more sources

Resistance to Trastuzumab

Cancers, 2022
Simple Summary Trastuzumab is a humanized antibody that has significantly improved the management and treatment outcomes of patients with cancers that overexpress HER2.
S. Vivekanandhan, K. Knutson
semanticscholar   +3 more sources

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

Nature Medicine, 2021
The applicability of circulating tumor DNA (ctDNA) genotyping to inform enrollment of patients with cancer in clinical trials has not been established.
Ken Kato, Satoshi Yuki, Hiromichi Ebi
exaly   +2 more sources

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Journal of Clinical Oncology, 2020
PURPOSE In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib.
Nancy U Lin, Virginia F Borges, Carey K Anders   +2 more
exaly   +2 more sources

Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production [PDF]

Frontiers in Physiology, 2018
The ErbB2 blocker trastuzumab improves survival in oncologic patients, but can cause cardiotoxicity. The late Na+ current inhibitor ranolazine has been shown to counter experimental HF, including doxorubicin cardiotoxicity (a condition characterized by ...
Gennaro Riccio, Salvatore Antonucci, Carmela Coppola, Chiara D'Avino, Chiara D'Avino, Giovanna Piscopo, Danilo Fiore, Carlo Maurea, Michele Russo, Domenica Rea, Claudio Arra, Gerolama Condorelli, Fabio Di Lisa, Carlo G. Tocchetti, Claudia De Lorenzo, Claudia De Lorenzo, Nicola Maurea   +16 more
doaj   +5 more sources

circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer

Molecular Cancer, 2022
Background Approximate 25% HER2-positive (HER2+) breast cancer (BC) patients treated with trastuzumab recurred rapidly. However, the mechanisms underlying trastuzumab resistance remained largely unclear.
Yun Ling, Gehao Liang, Qun Lin, Xiaolin Fang, Qing Luo, Yinghuan Cen, Maryam Mehrpour, Ahmed Hamai, Zihao Liu, Yu Shi, Juanmei Li, Wanyi Lin, Shijie Jia, Wenqian Yang, Qiang Liu, Erwei Song, Jun Li, Chang Gong   +17 more
doaj   +2 more sources

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents

Frontiers in Oncology, 2022
Trastuzumab is a standard molecular targeted therapy for human epidermal growth factor receptor 2(HER2) -positive breast cancer, which can significantly improve the survival of patients with this molecular subtype of breast cancer.
Zhen-hao Wang, Zhen-hao Wang, Zhuo-qun Zheng, Shi−cheng Jia, Shu-ni Liu, Xiao-fen Xiao, Xiao-fen Xiao, Guan-yuan Chen, Guan-yuan Chen, Wei-quan Liang, Wei-quan Liang, Xiao-feng Lu, Xiao-feng Lu   +12 more
doaj   +2 more sources

Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab

Signal Transduction and Targeted Therapy, 2021
Despite the successful use of the humanized monoclonal antibody trastuzumab (Herceptin) in the clinical treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer, the frequently occurring drug resistance remains to be ...
Weimiao Li, An-Gang Yang, Lin-Tao Jia
exaly   +2 more sources

Efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer: a systematic review and network meta-analysis [PDF]

BMC Cancer
Objective This study aimed to evaluate the efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer using a network meta-analysis approach.
Chaoyang Wang, Dong Xiao, Chao Zhai
doaj   +2 more sources